Literature DB >> 2371776

In vitro regulation of human hepatitis B virus core gene transcription.

A Waisman1, Y Aloni, O Laub.   

Abstract

In the present study we used a HeLa whole cell extract transcription system to map the transcription start sites and the minimal promoter of the hepatitis B virus core gene. Two initiation sites located at residues 1792 +/- 5 and 1817 +/- 5 were identified. The minimal upstream region essential and sufficient for transcription was defined to a 105-base pair DNA fragment. These results are identical to the in vivo mapping of the transcription start sites and the minimal core gene promoter. When in vitro transcription elongation was carried out in the presence of the anionic detergent Sarkosyl, known to enhance premature transcription termination (attenuation), two short transcripts (as well as two run-offs) were synthesized. Kinetic studies indicated that the short transcripts resulted from a block to transcription elongation and not from RNA processing. RNA mapping showed that the short attenuated transcripts indeed initiated at the two core gene initiation sites and both prematurely terminated at nucleotide 1966 +/- 5, defined as the attenuation site. This site is located in the attenuator RNA within a uridine-rich sequence preceded by a stable hairpin structure. Attenuation at the same site occurred when transcription of the core gene was directed by the Ad2 major late promoter (MLP) and when the poly(A) signal, which precedes the attenuation site, was mutated from TATAAA to TAGAAA. We suggest that the elongation block at nt 1966 +/- 5 in vivo exerts a dual function: first, it regulates the level of RNA by attenuation during the first cycle of transcription and, second, it acts as a termination site at the end of the primary RNA transcript.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2371776     DOI: 10.1016/0042-6822(90)90540-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells.

Authors:  Debomoy K Lahiri; Bryan Maloney; Yuan-Wen Ge
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  In vitro analysis of elongation and termination by mutant RNA polymerases with altered termination behavior.

Authors:  S A Shaaban; E V Bobkova; D M Chudzik; B D Hall
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

3.  Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated.

Authors:  X Yu; J E Mertz
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

4.  Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture.

Authors:  H Tang; A K Raney; A McLachlan
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Members of the nuclear receptor superfamily regulate transcription from the hepatitis B virus nucleocapsid promoter.

Authors:  A K Raney; J L Johnson; C N Palmer; A McLachlan
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.

Authors:  A Waisman; P J Ruiz; E Israeli; E Eilat; S Könen-Waisman; H Zinger; M Dayan; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

7.  Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor.

Authors:  A K Raney; H B Le; A McLachlan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Characterization of functional Sp1 transcription factor binding sites in the hepatitis B virus nucleocapsid promoter.

Authors:  P Zhang; A K Raney; A McLachlan
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.